Dental biofilm, often described as a group of microorganisms embedded in an extracellular polysaccharide (EPS) matrix attached to the tooth surface, is responsible for multiple diseases occurring in the oral cavity (e.g. dental caries). Great attention is paid to the bacterially derived polysaccharide matrix in the pathogenesis of these biofilm-dependent diseases ([@CIT0001]). The polysaccharide matrix can extensively modulate the virulence of biofilm by enhancing initial adherence of microorganisms and bacterial coherence, affecting transport of nutrients, acting as reserve supply of carbohydrate, and protecting the microbial community from inimical stimulus ([@CIT0002]--[@CIT0006]).

It is also recognized that a group of exoenzymes named glucosyltransferases (Gtfs) play critical roles in the synthesis of EPS, providing sites on dental surfaces for microbial colonization, adherent glucan for bacterial coherence, and water-insoluble matrix for biofilm formation. As a major etiological pathogen of dental caries, *Streptococcus mutans* is also regarded as the key contributor to EPS ([@CIT0004], [@CIT0007]). *S. mutans* expresses at least three genetically separate Gtfs: GtfB, which synthesizes primarily insoluble glucans rich in α-1,3 glycosidic linkages; GtfC, which produces a mixture of insoluble and soluble glucans (with α-1,6-linkages); and GtfD, which synthesizes predominantly soluble glucans. Each plays a distinct but overlapping role ([@CIT0008]--[@CIT0010]). GtfC has the greatest affinity for saliva-coated hydroxyapatite (sHA) with enhanced activity when it is adsorbed to sHA, thus enhancing the adherence of bacterial cells to dental surfaces, whereas GtfB binds with greater avidity to many oral bacteria including those that do not express Gtfs, thereby converting them into glucan formers and promoting cell accumulation in the biofilm ([@CIT0011]). GtfD, however, synthesizes mainly water-soluble glucans, which serve as primers for GtfB ([@CIT0012]). The formation and structure of glucans synthesized by Gtfs, particularly by GtfB, is also modulated by starch hydrolysates, which include a range of degradation products of starch digested by salivary α-amylase ([@CIT0013]). The hydrolysates serve as acceptors for polymer formation and substrate for the addition of branches even without supply of sucrose ([@CIT0014]--[@CIT0016]).

It is noteworthy that a similar basic structure is found in all Gtfs encoded by *S. mutans* ([@CIT0011], [@CIT0017], [@CIT0018]), particularly the highly homologous GtfB and GtfC, which shares approximately 75% amino acid sequence identity ([@CIT0019]). The sequence of glucosyltransferase gene (*gtfI*) from cariogenic *Streptococcus sobrinus* also showed a high degree of homology with *gtfB* of *S. mutans* ([@CIT0017]). Gtfs are large enzymes with an average molecular mass of approximately 160 kDa. All Gtfs are composed of three functional regions: the N-terminal variable junction region, the C-terminal glucan-binding region, and the highly conserved catalytic region, which is essential for glucan synthesis of Gtfs ([@CIT0020], [@CIT0021]). Gtf has at least two subsites, glucosyl and fructosyl, which could be potential targets for inhibitory agents ([@CIT0022]). Recently, the crystallization and X-ray analysis for GtfC from *S. mutans* was reported, and the detailed structural information on GtfC catalytic domain was revealed ([@CIT0023]). It is also noteworthy that GtfC, particularly its C terminus, has many hydrophobic domains ([@CIT0019]), which can explain its remarkable resistance to inhibitory agents as these domains may block access by hydrophilic inhibitors to the active site. These researches provided instrumental data, opportunities, and also challenges for the development of novel chemotherapeutic agents targeting Gtfs to control biofilm-related diseases.

Following recognition of the etiologic importance and biology of Gtfs ([@CIT0007]), inhibition of Gtf activity (particularly GtfC and GtfB) and polysaccharide synthesis as an approach to prevent biofilm-related diseases has started to draw attention. This approach has been advocated by Bowen and Koo ([@CIT0007]) and many others. These enzymes are attractive drug targets for the development of therapeutics for dental caries, as such a selective approach on a proven virulence may confer selectivity against the pathogen with minimal effect on other commensal microbes. However, it is notable that an agent that inhibits Gtf in solution may not necessarily work when the enzyme is adsorbed to a surface ([@CIT0024]) and agents effective *in vitro* may not have the capacity to modulate the pathogenesis of dental caries *in vivo*. The polyphenolic compounds derived from natural products have been studied extensively for years and were found to display potent antimicrobial activity by mechanisms, including the inhibition of Gtfs. Another strategy to inhibit polysaccharide synthesis is to screen or even design novel small molecules that bind specifically to the enzymatic site of Gtf and inhibit its catalytic activity. The aim of this current review is to provide an up-to-date account of researches into molecules ([Table 1](#T0001){ref-type="table"}) that target bacterial polysaccharide synthesis by inhibition of Gtf activity.

###### 

Molecules that inhibit glycosyltransferase activity

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Category                                   Source of natural product                           Representative substances           Inhibited Gtfs reported                   Evidence of cariostatic efficacy *in vivo*                                         Reference
  ------------------------------------------ --------------------------------------------------- ----------------------------------- ----------------------------------------- ---------------------------------------------------------------------------------- --------------------------------------
  Inhibitors derived from natural products                                                                                                                                                                                                                        

   Catechin-based polyphenols                *Camellia sinensis* (black, green and oolong tea)   Theaflavin\                         GtfB (solution)\                          Yes (as crude tea extract) Yes (as crude tea extract) Yes (as crude tea extract)   ([@CIT0026]--[@CIT0031])
                                                                                                 \                                   \                                                                                                                            
                                                                                                 (-)-Epigallocatechin gallate\       GtfB (solution)\                                                                                                             
                                                                                                 \                                   \                                                                                                                            
                                                                                                 (-)-Epicatechin gallate             GtfB (solution)                                                                                                              

   Flavonoids                                *Apis mellifera propolis* (bee hive)                Apigenin                            GtfB, GtfC, and GtfD (solution/surface)   Yes                                                                                ([@CIT0036], [@CIT0037])

                                                                                                 Kaempferol                          GtfB, GtfC, and GtfD (solution/surface)   No                                                                                 ([@CIT0036])

                                             *Vaccinium macrocarpon* (cranberry)                 Myricetin                           GtfB (surface)                            No                                                                                 ([@CIT0042])

   Proanthocyanidin oligomers                Cranberry                                           A-type proanthocyanidin oligomers   GtfB (surface)                            Yes                                                                                ([@CIT0042], [@CIT0043])

                                             Apple                                               Condensed tannins                   Crude Gtfs (solution)                     No                                                                                 ([@CIT0044])

   Polymeric polyphenols                     Oolong tea                                          OTF6                                GtfB and GtfD (solution)                  Yes (as crude tea extract)                                                         ([@CIT0026], [@CIT0048])

                                             Cocoa bean hust                                     Polymeric epicatechins              GtfB, GtfC, and GtfD (solution)           No                                                                                 ([@CIT0049], [@CIT0050])

   Others                                    *Rheedia gardneriana*                               7-Epiclusianone                     GtfB and GtfC (solution)                  No                                                                                 ([@CIT0051])

                                             *Azadirachta indica* (Neem)\                        Gallotannin\                        Crude Gtfs (solution)\                    No\                                                                                ([@CIT0052])\
                                             *Melaphis chinensis* (Chinese Nutgall)              Gallotannin                         Crude Gtfs (solution)                     No                                                                                 ([@CIT0053])

                                                                                                                                                                                                                                                                  

  Synthesized inhibitors                                                                                                                                                                                                                                          

                                                                                                 Quaternary ammonium                 Crude Gtfs (solution)                     No                                                                                 ([@CIT0054])

                                                                                                 Aliphatic amines                    Crude Gtfs (solution)                     No                                                                                 ([@CIT0054])

                                                                                                 1-Deoxynojirimycin                  GtfB, GtfC, and GtfD (solution/surface)   No                                                                                 ([@CIT0024], [@CIT0057])

                                                                                                 Tris(hydroxymethyl) aminomethane    Crude Gtfs (solution/surface)             No                                                                                 ([@CIT0056])

                                                                                                 Trichloro-galactosucrose            GtfB, GtfC, and GtfD (solution/surface)   No                                                                                 ([@CIT0024])

                                                                                                 Acarbose                            GtfB, GtfD (solution)                     No                                                                                 ([@CIT0057])

                                                                                                 Maltose                             GtfB (solution)                           No                                                                                 ([@CIT0057])

                                                                                                 Nojirimycin                         GtfB (solution)                           No                                                                                 ([@CIT0057])

                                                                                                 Quinoxaline derivative              GtfC and GtfD (solution)                  Yes                                                                                ([@CIT0058])

                                                                                                                                                                                                                                                                  

  Metal ions and oxidizing agents                                                                Zn^2+^                              GtfB, GtfC, and GtfD (solution)           No                                                                                 ([@CIT0024])

                                                                                                 Cu^2+^                              GtfB, GtfC, and GtfD (solution/surface)   No                                                                                 ([@CIT0024])

                                                                                                 Fe^2+^                              GtfB, GtfC, and GtfD (solution/surface)   No                                                                                 ([@CIT0024])

                                                                                                 Fe^3+^                              GtfB, GtfC, and GtfD (solution/surface)   No                                                                                 ([@CIT0024])

                                                                                                 Rose bengal                         GtfB, GtfC, and GtfD (solution/surface)   No                                                                                 ([@CIT0024])

                                                                                                 Hypochlorite                        GtfB, GtfC, and GtfD (solution/surface)   No                                                                                 ([@CIT0024])

  Antibodies                                                                                     Antibody to GtfB                    GtfB and GtfC (solution/surface)          Yes                                                                                ([@CIT0066], [@CIT0068], [@CIT0069])

                                                                                                 Antibody to GtfC                    GtfB and GtfC (solution/surface)          No                                                                                 ([@CIT0066])

                                                                                                 Antibody to GtfD                    GtfD (solution), GtfC (surface)           No                                                                                 ([@CIT0066])
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Possible biological effects of administration of Gtf inhibitors {#S0002}
===============================================================

As a proven virulence factor in the pathogenesis of dental caries ([@CIT0004], [@CIT0007]), Gtfs and their catalysates play a significant role in the development of dental plaque. Therefore, a reduction in initial formation and accumulation of biofilm is the most possible effect resulting from impaired polysaccharide synthesis and poor sucrose-dependent adherence due to inhibited Gtf activity. Additionally, the loss of Gtf activity is likely to make the plaque more susceptible to mechanical clearance, which is also an essential mechanism for the cariostatic effect of Gtf inhibitors *in vivo*. Another overlooked advantage of Gtf-targeting inhibitors is their potential to possess anti-biofilm activity without being bactericidal, thus providing alternative methods to prevent biofilm-related diseases with minimal effect on the ecological balance in the microbial community.

Gtf inhibitors derived from natural products {#S0003}
============================================

Natural products offer a diversity of structurally distinctive molecules with a wide range of biochemical specificities, which make them attractive and a major objective for drug discovery ([@CIT0025]). Among them, the polyphenols have been studied extensively in recent years, displaying anti-biofilm capacity by multiple mechanisms including direct inhibition of Gtf activity.

Catechin-based polyphenols {#S0004}
==========================

Various kinds of catechin-based polyphenols extracted from the leaves of *Camellia sinensis* (raw material of black, green, and oolong teas) have been shown to disrupt the enzymatic activity of Gtfs. Extracts of green tea, oolong tea and black tea were reported to reduce the development of caries on tooth surfaces in rats infected with *S. mutans* or *S. sobrinus* ([@CIT0026]--[@CIT0028]). Evidence *in vitro* indicated that the cariostatic effects of these compounds were related to their inhibitory effects of Gtfs rather than direct effects on the bacterial growth, with inhibitory activities of theaflavin, (-)-epigallocatechin gallate, and (-)-epicatechin gallate particularly noticeable ([@CIT0029]--[@CIT0031]). It was found that theaflavin derived from black tea extract produced 50% inhibition of purified GtfB in solution at the concentration of 8 µg/mL (10 µM) ([@CIT0030]). (-)-Epigallocatechin gallate and (-)-epicatechin gallate were reported to inhibit 23 and 28% of GtfB activity (in solution) at the concentration of 250 µg/mL (546 and 566 µM, respectively) ([@CIT0030]). Other possible mechanisms by which these catechin-based polyphenols are cariostatic include 1) direct antimicrobial bioactivity against *S. mutans*, 2) inhibitory effects on bacterial adherence and plaque accumulation, and 3) inhibition on acid production ([@CIT0032]--[@CIT0035]).

Flavonoids {#S0005}
==========

It has recently been shown that specific flavonols (e.g. kaempferol and myricetin) and flavones (e.g. apigenin) in *Apis mellifera propolis* (bee hive) displayed inhibitory effects against Gtfs derived from *S. mutans* ([@CIT0036]). Among them, apigenin (4′,5,7-trihydroxyflavone) was identified as the most effective non-competitive inhibitor of Gtfs, especially GtfB and GtfC, both in solution (90.5--95% inhibition) and on the surface of sHA (33--60.5% inhibition) at 500 µM (135 µg/mL) ([@CIT0036]). Its cariostatic activity was also validated *in vivo* ([@CIT0037]). Furthermore, it was speculated that the specific position of hydroxyl groups and the double bond between C2 and C3 may provide sites for nucleophilic addition by side chains of amino acid in Gtfs, which could diminish their activities ([@CIT0037]). Similar inhibitory effects were observed for kaempferol on Gtfs, both in solution (86.7--90.4% inhibition) and on the surface of sHA (28.5--40.2% inhibition) at 500 µM (143 µg/mL) ([@CIT0037]). Other biological activities possibly responsible for the cariostatic efficacy of flavonoids include 1) antimicrobial activity against planktonic cells and biofilms of *S. mutans*, 2) negative effects on acidogenic/aciduric properties, and 3) down-regulating *gtf* gene expression ([@CIT0036]--[@CIT0041]).

Proanthocyanidin oligomers {#S0006}
==========================

Aqueous extracts of cranberry have been shown to inhibit the synthesis of insoluble glucans by surface-adsorbed GtfB and GtfC, which was attributed mainly to the presence of flavonols and proanthocyanidin oligomers ([@CIT0042]). According to Koo et al. ([@CIT0043]), specific A-type proanthocyanidin oligomers (dimers to dodecamers) at the concentration of 0.1 mg/mL effectively diminished the synthesis of insoluble glucans by surface-adsorbed GtfB (40--70% inhibition) and the incidence/severity of smooth-surface caries in rats was markedly reduced by topical treatment of proanthocyanidins twice a day. Furthermore, the presence of A-type double interflavan linkage and a degree of polymerization (ranging from 4 to 12) was found to be optimal for the inhibition of surface-adsorbed enzyme ([@CIT0042], [@CIT0043]). Fruit-derived proanthocyanidin oligomers have also been recognized for their inhibitory activity against Gtfs of mutans streptococci. A study by Yanagida et al. has shown that apple polyphenols inhibit the activity of crude Gtfs in solution purified from *S. mutans* with no significant effect on the growth of the cariogenic bacteria ([@CIT0044]). The most potent Gtf inhibitors in apple polyphenols were apple condensed tannins, a mixture of procyanidins, the 50% inhibitory doses (ID~50~) of which against the crude Gtfs (in solution) of *S. sobrinus* and that of *S. mutans* were reported to be 1.5 and 5 µg/mL, respectively. Other possible mechanisms by which proanthocyanidin oligomers are caries preventing include: 1) antimicrobial activity against biofilms of *S. mutans*, 2) disruption of acidogenic/aciduric properties, and 3) enhanced detachment of biofilms of *S. mutans* ([@CIT0042], [@CIT0043], [@CIT0045]--[@CIT0047]).

Polymeric polyphenols {#S0007}
=====================

Matsumoto et al. demonstrated that the oolong tea fraction rich in high-molecular-weight polymeric polyphenols inhibited glucan synthesis by recombinant *S. mutans* GtfB and GtfD in solution non-competitively, with ID~50~ against GtfB and GtfD to be 60 and 100 µg/mL, respectively ([@CIT0048]). They also reported that the mechanism of Gtf inhibition by these polymeric polyphenols was related to their activities targeting the C-terminal glucan-binding domain of GtfB and GtfD. Other researches showed that high-molecular-weight polymeric proanthocyanidins, consisting of epicatechin units with C-4β and C-8 intermolecular bonds, were the major compounds with inhibitory bioactivities against Gtfs in cocoa bean husk extracts ([@CIT0049]). The crude ethanol extract inhibited the glucan synthesis of recombinant GtfB, C, and D in solution by 57%, 24%, and 26%, respectively, at the concentration of 1 mg/mL and the most active fraction, which contained 58.9% polyphenolic compounds, showed 68% inhibition at the concentration of 50 µg/mL(ID~50~=20 µg/mL). It was also reported that increasing polymerization of monomeric polyphenol was likely to improve their inhibitory effectiveness as a result of enhanced non-specific binding and precipitation of the enzymes ([@CIT0050]).

Others {#S0008}
======

7-Epiclusianone, a prenylated benzophenone isolated from the plant *Rheedia gardneriana*, was reported to be a potent inhibitor of purified GtfB and GtfC in solution, with 91.7% inhibition of GtfB and 84.1% inhibition of GtfC at the concentration of 100 µg/mL ([@CIT0051]). It was also revealed that the inhibition of GtfB was non-competitive, whereas GtfC was inhibited uncompetitively ([@CIT0051]). Furthermore, the inhibitory effect of gallotannin in the aqueous extract derived from the sticks of neem (*Azadirachta indica*) upon insoluble glucan synthesis by mixed Gtfs in solution was shown by Wolinsky et al. (71% inhibition at 250 µg/mL) ([@CIT0052]), while the same active constituent was also found in the ethanolic extracts from the Chinese Nutgall (*Melaphis chinensis*), exhibiting strong inhibition of crude Gtfs in solution of *S. sobrinus* origin with more than 91% inhibition of water-insoluble glucan synthesis from sucrose at the concentration of 7.8 µg/mL ([@CIT0053]).

Synthesized Gtf inhibitors {#S0009}
==========================

Results from early work showed that wide-ranging synthesized compounds, such as quaternary ammonium compounds and aliphatic amines, were effective to varying degrees in inhibiting undetermined mixtures of Gtfs in solution ([@CIT0054]). Meanwhile, 1-deoxynojirimycin, tris(hydroxymethyl) aminomethane, and trichloro-galactosucrose were shown to possess similar inhibitory activities against the Gtfs regardless of whether the enzymes were free in solution or adsorbed probably by binding to the aspartic acids in the active site and by blocking the formation of glucose transition molecules ([@CIT0024], [@CIT0055]--[@CIT0057]). Among them, 1-deoxynojirimycin was more effective against either GtfB or GtfC than it was against GtfD and possessed similar inhibition profiles for Gtfs both in solution and those adsorbed to sHA ([@CIT0024]). At 10 mM (163 µg/mL), the inhibitory effects on activities of solution-phase GtfB, C, and D were 33%, 44%, and 13%; and the numbers for surface-adsorbed GtfB, C, and D were 50%, 54%, and 11%, respectively ([@CIT0024]). According to Newbrun et al. ([@CIT0057]), acarbose effectively inhibited the synthesis of polysaccharide by *S. mutans* Gtf (at 20 mM, synthesis of water-insoluble glucan was completely blocked) and was more potent than other inhibitors such as maltose, nojirimycin, or amino sugars; and the mechanism of action of all these agents is consistent with competitive inhibition.

Recently, we screened a library of approximately 150,000 small drug-like compounds *in silico* against the structure of substrate-binding site of *S. mutans* GtfC and identified a quinoxaline derivative as a Gtf inhibitor ([@CIT0058]). We found that at the concentration of 10 µg/mL (23.3 µM), the quinoxaline derivative was capable of inhibiting water-insoluble glucan synthesis (60% reduction) and biofilm formation (79% reduction) *in vitro*. Zymogram assays revealed that solution-phase GtfC and GtfD were antagonized by the compound. It was noticeable that it also significantly reduced the incidence and severity of caries in a rat model with a concomitant reduction of the percentage of *S. mutans* in the animals' dental plaque. This is the first report of Gtf inhibitor identified through structure-based virtual screening, and the structure identified could serve as a chemical entry point for further antibiotic development.

Another work was done more recently by Mesleh et al. ([@CIT0059]), whose research had focused on the discovery of compounds with peptidoglycan glycosyltransferase inhibitory activity. Unlike the *S. mutans* Gtfs, this peptidoglycan glycosyltransferase enzyme transfers the disaccharide peptide from lipid II onto the growing glycan chain in the biosynthesis of bacterial cell wall peptidoglycan, thereby inhibiting the transglycosylation process results in the inhibition of bacterial growth in many Gram-positive organisms. They identified the minimal pharmacophore of a natural peptidoglycan glycosyltransferase inhibitor, moenomycin, as the key feature required for inhibitory activity before using this structure as a template to design novel enzyme inhibitors. The ID~50~ of their most potent inhibitor against *Staphylococcus aureus* glycosyltransferase was as low as 7.3 µM.

Metal ions and oxidizing agents as Gtf inhibitors {#S0010}
=================================================

Metal ions and some oxidizing agents have also been shown by some early studies to exhibit inhibitory activities against Gtfs. According to Wunder and Bowen ([@CIT0024]), activities of isolated GtfB, C, and D of the solution phase were inhibited significantly by the metal ions Zn^2+^, Cu^2+^, Fe^2+^, and Fe^3+^ (approximately 40--80% inhibition at 5 mM) and by rose bengal at 1 mM and hypochlorite at 10 mM (approximately 80--90% inhibition), whereas surface-adsorbed Gtfs displayed stronger resistance to the same metal cations and oxidizing compounds that inhibited them in solution. It is also clear that metal ions exert their inhibitory effects by taking advantage of a Fenton reaction in which they combine with peroxide to produce hydroxyl radical ions that are capable to inactivate Gtf enzymes ([@CIT0060]).

Antibody {#S0011}
========

*Streptococcus mutans* Gtfs and their fragments were shown to be immunogenic ([@CIT0061]), and antibodies that inhibit one or more Gtfs have been developed as topical agents.

Numerous antibody preparations were reported to inhibit sucrose-dependent aggregation, cell adhesion ([@CIT0062]--[@CIT0064]), and glucan synthesis by solution-phase GtfB, C, and D *in vitro* ([@CIT0065]). Wunder and Bowen ([@CIT0066]) used purified *S. mutans* GtfB, GtfC, or GtfD both in soluble form and surface-adsorbed to immunize rabbits and tested the antibodies for their inhibitory effects on Gtf activity. They found that antibodies to GtfB or GtfC inhibited the activity of solution-phase GtfB and GtfC by over 90% but had lesser effects against the same enzymes adsorbed to sHA (70--80%) and no effect on GtfD. Antibodies to GtfD had strong inhibitory activity against GtfD in solution (80--90%) and modest effects on GtfC bound to sHA, but no inhibition was observed for surface-adsorbed GtfD, solution-phase GtfC, and GtfB of both phases. Their data showed that antibodies effective against Gtf in one phase may react differently against the same enzyme in the other phase. It was also reported by Kopec et al. ([@CIT0067]) that the structure of glucans synthesized by GtfB and GtfC in the presence of a polyclonal antiserum to mixed Gtfs differed from that of controls in glycosidic linkages, susceptibilities to mutanase/dextranase, and also hydrolysates from the enzymatic digestion.

Antibodies to various preparations of Gtf have been raised and applied topically to determine their effects on caries development *in vivo*. It was revealed that topical application of antibody to GtfB was effective in reducing the incidence of caries in rats ([@CIT0068], [@CIT0069]). It was also noted that passive immunization with bovine milk containing antibodies to hybrid GtfB and cell surface protein antigen (PAc) suppressed caries development in a rat model ([@CIT0070]).

Conclusion {#S0012}
==========

Since the cariogenic species are essential components in the microecological balance of oral flora, it would be not just unproductive but often counterproductive to eradicate them from the entire microbial population by antibiotic treatment. Therefore, it may be more rewarding to seek new strategies for inhibiting their key virulence without wiping them out. It is also well established that EPS are essential for the development of cariogenic biofilms and that mutans streptococci are the primary producers of the EPS-rich matrix through Gtfs, as reviewed by Koo et al. ([@CIT0001]). Those exoenzymes synthesized by *S. mutans* are capable of converting many other species into cooperative EPS producers by adsorbing to their surfaces ([@CIT0011]). Consequently, the elevated amounts of EPS will promote the accumulation of a number of different oral microorganisms on tooth surfaces and increase the stability of the biofilm, enhancing its virulence ([@CIT0071]). Therefore, targeting the Gtf enzymes synthesized by *S. mutans* could be significant for therapeutic interventions to prevent dental caries, even though it is increasingly evident that caries is the result of the bacterial consortium acting together in the dental biofilm rather than the infection of a specific pathogen ([@CIT0072]).

Other oral streptococci, such as *S. sanguinis*, *S. oralis*, and *S. gordonii*, also express Gtf enzyme and produce water-soluble glucans, which may contribute to the overall polysaccharide synthesis in the extracellular matrix and enhance adhesion of organisms producing water-insoluble glucans ([@CIT0073], [@CIT0074]). As our preliminary study showed, the inhibitor of *S. mutans* Gtfs resulted in poor biofilm formation for both *S. mutans* and *S. sanguinis*, but did not affect the biofilm formed by *S. gordonii* ([@CIT0058]). In addition, the inhibitory profile on the formation of three-species biofilm was similar to those of the monospecies biofilms formed by *S. mutans* or *S. sanguinis* ([@CIT0058]). However, evidence is still lacking that how the molecules targeting *S. mutans* Gtfs will affect the entire biofilm community, including the Gtf activities of other oral streptococci, and the possible effects on a health-associated microbiota. Therefore, much research remains to be performed from the point of microecology to represent a complete picture of the overall influence of this strategy on oral community.

Currently, a wide range of Gtf inhibitors have been discovered that can be broadly classed as either synthetic inhibitors or inhibitors from natural sources. With the possibility of screening large quantities of drug-like compounds against the active sites of Gtfs and designing new inhibitors using the key structures of known sites (both synthesized and natural) as templates, it is very likely that more effective molecules targeting Gtfs will continue to be discovered, and some of them may eventually be ready for therapeutic use. Although many of the available inhibitors are highly effective *in vitro*, it is still unclear whether they are suitable for *in vivo* use, and their cariostatic efficacies and mechanisms remain largely unknown. Therefore, further research is required to reveal the mechanism of ligand--enzyme interaction at the molecular level and assess treatments in animal experiments or even clinical trials before any conclusions can be made. In the meantime, comprehensive toxicological tests and safety studies should be performed both topically and systemically, even if the molecule is derived from natural products (traditional medicine, plant-derived foods, and so on), which are generally not expected to be toxic.
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